Plants vs. cancer: A review on natural phytochemicals in preventing and treating cancers and their druggability

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1281-1305

  Wang, Hu ^a   Khor, Tin Oo ^a   Shu, Limin ^a   Su, Zheng Yuan ^a   Fuentes, Francisco ^a   Lee, Jong Hun ^a   Kong, Ah Ng Tony ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Anti cancer; Chemoprevention; Druggability; Mechanism; Natural compounds; Pathway; Phytochemical

Indexed keywords

3 INDOLEMETHANOL; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; APIGENIN; CROCETIN; CURCUMIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; FISETIN; GENISTEIN; GINGEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAEMPFEROL; LYCOPENE; MICRORNA; PHENETHYL ISOTHIOCYANATE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLANT MEDICINAL PRODUCT; POLO LIKE KINASE 1; PROTEIN P53; RESVERATROL; ROSMARINIC ACID; SHOGAOL; SONIC HEDGEHOG PROTEIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNINDEXED DRUG; VITAMIN D;

APOPTOSIS; APPLE; ARTICLE; BRASSICA; BROCCOLI; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EPIGENETICS; GINGER; GRAPEFRUIT; HISTONE MODIFICATION; HUMAN; MUSHROOM; NEOPLASM; NONHUMAN; PARSLEY; PROTEIN EXPRESSION; ROSEMARY; SOYBEAN; STRAWBERRY; TEA; TOMATO;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AGENTS; CHEMOPREVENTION; HUMANS; NEOPLASMS; PLANT PREPARATIONS;

EID: 84870195172     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803833026     Document Type: Article

References (324)

1. Davies, G. Time Tables of Medicine, Black Dog & Leventhal: New York, 2000.
2. Gutheil, W. G.; Reed, G.; Ray, A.; Dhar, A. Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer. Curr. Pharm. Biotechnol., 2011.13(1), 173-179.
3. Meeran, S. M.; Ahmed, A.; Tollefsbol, T. O. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin. Epigenetics, 2010, 1 (3-4), 101-116.
4. Karikas, G. A. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J. Buon., 2010, 15 (4), 627-638.
5. Saunders, F. R.; Wallace, H. M. On the natural chemoprevention of cancer. Plant Physiol. Biochem., 2010, 48 (7), 621-626.
6. Sarkar, F. H.; Li, Y.; Wang, Z.; Padhye, S. Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs. Curr. Pharm. Des., 2010, 16 (16), 1801-1812.
7. Mehta, R. G.; Murillo, G.; Naithani, R.; Peng, X. Cancer chemoprevention by natural products: how far have we come? Pharm. Res., 2010, 27 (6), 950-961.
8. Gullett, N. P.; Ruhul Amin, A. R.; Bayraktar, S.; Pezzuto, J. M.; Shin, D. M.; Khuri, F. R.; Aggarwal, B. B.; Surh, Y. J.; Kucuk, O. Cancer prevention with natural compounds. Semin. Oncol., 2010, 37 (3), 258-281.
9. Chen, J.; Xu, X. Diet, epigenetic, and cancer prevention. Adv. Genet., 2010, 71 237-255.
10. Huang, W. Y.; Cai, Y. Z.; Zhang, Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr. Cancer, 2010, 62 (1), 1-20.
11. Huang, J.; Plass, C.; Gerhauser, C. Cancer Chemoprevention by Targeting the Epigenome. Curr. Drug Targets, 2011, 12(13), 1925-1956.
12. Shu, L.; Cheung, K. L.; Khor, T. O.; Chen, C.; Kong, A. N. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev., 2010, 29 (3), 483-502.
13. Viola, V.; Pilolli, F.; Piroddi, M.; Pierpaoli, E.; Orlando, F.; Provinciali, M.; Betti, M.; Mazzini, F.; Galli, F. Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E. Genes Nutr., 2012, 7(1), 29-41.
14. Bishayee, A.; Ahmed, S.; Brankov, N.; Perloff, M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front. Biosci., 2011, 16, 980-996.
15. Colombo, M. L. An update on vitamin E, tocopherol and tocotrienol-perspectives. Molecules, 2010, 15 (4), 2103-2113.
16. Scorei, R. I.; Popa, R., Jr. Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anticancer Agents Med. Chem., 2010, 10 (4), 346-351.
17. Granados-Principal, S.; Quiles, J. L.; Ramirez-Tortosa, C. L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M. C. Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutr. Rev., 2010, 68 (4), 191-206.
18. Marques, F. Z.; Markus, M. A.; Morris, B. J. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int. J. Biochem. Cell Biol., 2009, 41 (11), 2125-2128.
19. Patisaul, H. B.; Jefferson, W. The pros and cons of phytoestrogens. Front. Neuroendocrinol., 2010, 31 (4), 400-419.
20. Al-Azzawi, F.; Wahab, M. Effectiveness of phytoestrogens in climacteric medicine. Ann. N Y Acad. Sci., 2010, 1205 262-267.
21. Kim, J. W.; Amin, A. R.; Shin, D. M. Chemoprevention of head and neck cancer with green tea polyphenols. Cancer Prev. Res. (Phila), 2010, 3 (8), 900-909.
22. Pan, M. H.; Lai, C. S.; Wu, J. C.; Ho, C. T. Molecular mechanisms for chemoprevention of colorectal cancer by natural dietary compounds. Mol. Nutr. Food Res., 2011, 55 (1), 32-45.
23. Olejnik, A.; Tomczyk, J.; Kowalska, K.; Grajek, W. [The role of natural dietary compounds in colorectal cancer chemoprevention]. Postepy. Hig. Med. Dosw. (Online), 2010, 64 175-187.
24. Callahan, R.; Hurvitz, S. Human epidermal growth factor receptor- 2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr. Opin. Obstet. Gynecol., 2011, 23 (1), 37-43.
25. Rahman, M. A.; Amin, A. R.; Shin, D. M. Chemopreventive potential of natural compounds in head and neck cancer. Nutr. Cancer, 2010, 62 (7), 973-987.
26. Stan, S. D.; Singh, S. V.; Brand, R. E. Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol., 2010, 7 (6), 347-356.
27. Trottier, G.; Bostrom, P. J.; Lawrentschuk, N.; Fleshner, N. E. Nutraceuticals and prostate cancer prevention: a current review. Nat. Rev. Urol., 2010, 7 (1), 21-30.
28. Hu, R.; Saw, C. L.; Yu, R.; Kong, A. N. Regulation of NF-E2- related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid. Redox Signal, 2010, 13 (11), 1679-1698.
29. Cerella, C.; Sobolewski, C.; Dicato, M.; Diederich, M. Targeting COX-2 expression by natural compounds: a promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem. Pharmacol., 2010, 80 (12), 1801-1815.
30. Schmit, T. L.; Ledesma, M. C.; Ahmad, N. Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm. Res., 2010, 27 (6), 989-998.
31. Jeong, S. J.; Koh, W.; Lee, E. O.; Lee, H. J.; Lee, H. J.; Bae, H.; Lu, J.; Kim, S. H. Antiangiogenic phytochemicals and medicinal herbs. Phytother. Res., 2011, 25 (1), 1-10.
32. Leonarduzzi, G.; Testa, G.; Sottero, B.; Gamba, P.; Poli, G. Design and development of nanovehicle-based delivery systems for preventive or therapeutic supplementation with flavonoids. Curr. Med. Chem., 2010, 17 (1), 74-95.
33. Hoensch, H. P.; Oertel, R. Emerging role of bioflavonoids in gastroenterology: Especially their effects on intestinal neoplasia. World J. Gastrointest. Oncol., 2011, 3 (5), 71-74.
34. El-Alfy, T. S.; Ezzat, S. M.; Hegazy, A. K.; Amer, A. M.; Kamel, G. M. Isolation of biologically active constituents from Moringa peregrina (Forssk.) Fiori. (family: Moringaceae) growing in Egypt. Pharmacogn. Mag., 2011, 7 (26), 109-115.
35. Ferreira, C. V.; Justo, G. Z.; Souza, A. C.; Queiroz, K. C.; Zambuzzi, W. F.; Aoyama, H.; Peppelenbosch, M. P. Natural compounds as a source of protein tyrosine phosphatase inhibitors: application to the rational design of small-molecule derivatives. Biochimie., 2006, 88 (12), 1859-1873.
36. Chung, C. S.; Jiang, Y.; Cheng, D.; Birt, D. F. Impact of adenomatous polyposis coli (APC) tumor supressor gene in human colon cancer cell lines on cell cycle arrest by apigenin. Mol. Carcinog., 2007, 46 (9), 773-782.
37. Turktekin, M.; Konac, E.; Onen, H. I.; Alp, E.; Yilmaz, A.; Menevse, S. Evaluation of the Effects of the Flavonoid Apigenin on Apoptotic Pathway Gene Expression on the Colon Cancer Cell Line (HT29). J. Med. Food, 2011, 14(10), 1107-1117.
38. Leonardi, T.; Vanamala, J.; Taddeo, S. S.; Davidson, L. A.; Murphy, M. E.; Patil, B. S.; Wang, N.; Carroll, R. J.; Chapkin, R. S.; Lupton, J. R.; Turner, N. D. Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp. Biol. Med. (Maywood), 2010, 235 (6), 710-717.
39. Bruno, A.; Siena, L.; Gerbino, S.; Ferraro, M.; Chanez, P.; Giammanco, M.; Gjomarkaj, M.; Pace, E. Apigenin affects leptin/leptin receptor pathway and induces cell apoptosis in lung adenocarcinoma cell line. Eur. J. Cancer, 2011, 47(13), 2042-2051.
40. Ye, Y.; Wang, H.; Chu, J. H.; Chou, G. X.; Yu, Z. L. Activation of p38 MAPK pathway contributes to the melanogenic property of apigenin in B16 cells. Exp. Dermatol., 2011, 20(9), 755-757.
41. Clere, N.; Faure, S.; Martinez, M. C.; Andriantsitohaina, R. Anticancer properties of flavonoids: roles in various stages of carcinogenesis. Cardiovasc. Hematol. Agents Med. Chem., 2011, 9 (2), 62-77.
42. Bachmeier, B. E.; Mirisola, V.; Romeo, F.; Generoso, L.; Esposito, A.; Dell'eva, R.; Blengio, F.; Killian, P. H.; Albini, A.; Pfeffer, U. Reference profile correlation reveals estrogen-like trancriptional activity of Curcumin. Cell Physiol. Biochem., 2010, 26 (3), 471-482.
43. Senft, C.; Polacin, M.; Priester, M.; Seifert, V.; Kogel, D.; Weissenberger, J. The nontoxic natural compound Curcumin exerts anti-proliferative, anti-migratory, and anti-invasive properties against malignant gliomas. BMC Cancer, 2010, 10, 491.
44. Bachmeier, B. E.; Mohrenz, I. V.; Mirisola, V.; Schleicher, E.; Romeo, F.; Hohneke, C.; Jochum, M.; Nerlich, A. G.; Pfeffer, U. Curcumin downregulates the inflammatory cytokines CXCL1 and - 2 in breast cancer cells via NFkappaB. Carcinogenesis, 2008, 29 (4), 779-789.
45. Aggarwal, B. B.; Shishodia, S. Suppression of the nuclear factor- kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N Y Acad. Sci., 2004, 1030 434-441.
46. Beevers, C. S.; Chen, L.; Liu, L.; Luo, Y.; Webster, N. J.; Huang, S. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res., 2009, 69 (3), 1000-1008.
47. Ravindran, J.; Prasad, S.; Aggarwal, B. B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J., 2009, 11 (3), 495-510.
48. Su, C. C.; Chen, G. W.; Lin, J. G.; Wu, L. T.; Chung, J. G. Curcumin inhibits cell migration of human colon cancer colo 205 cells through the inhibition of nuclear factor kappa B /p65 and down-regulates cyclooxygenase-2 and matrix metalloproteinase-2 expressions. Anticancer Res., 2006, 26 (2A), 1281-1288.
49. Chen, A.; Xu, J.; Johnson, A. C. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene, 2006, 25 (2), 278-287.
50. Johnson, S. M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B. M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res., 2009, 29 (8), 3185-3190.
51. Epstein, J.; Docena, G.; MacDonald, T. T.; Sanderson, I. R. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br. J. Nutr., 2010, 103 (6), 824-832.
52. Epstein, J.; Sanderson, I. R.; Macdonald, T. T. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr., 2010, 103 (11), 1545-1557.
53. Jeong, W. S.; Kim, I. W.; Hu, R.; Kong, A. N. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm. Res., 2004, 21 (4), 649-660.
54. Jeong, W. S.; Kim, I. W.; Hu, R.; Kong, A. N. Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm. Res., 2004, 21 (4), 661-670.
55. Shen, G.; Xu, C.; Hu, R.; Jain, M. R.; Gopalkrishnan, A.; Nair, S.; Huang, M. T.; Chan, J. Y.; Kong, A. N. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5 (1), 39-51.
56. Yu, S.; Shen, G.; Khor, T. O.; Kim, J. H.; Kong, A. N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther., 2008, 7 (9), 2609-2620.
57. Cheung, K. L.; Khor, T. O.; Kong, A. N. Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm. Res., 2009, 26 (1), 224-231.
58. Saw, C. L.; Huang, Y.; Kong, A. N. Synergistic anti-inflammatory effects of low doses of curcumin in combination with poly- unsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol., 2010, 79 (3), 421-430.
59. Khor, T. O.; Keum, Y. S.; Lin, W.; Kim, J. H.; Hu, R.; Shen, G.; Xu, C.; Gopalakrishnan, A.; Reddy, B.; Zheng, X.; Conney, A. H.; Kong, A. N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res., 2006, 66 (2), 613-621.
60. Kim, J. H.; Xu, C.; Keum, Y. S.; Reddy, B.; Conney, A.; Kong, A. N. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis, 2006, 27 (3), 475-482.
61. Amin, A.; Hamza, A. A.; Bajbouj, K.; Ashraf, S. S.; Daoud, S. Saffron: A potential target for a novel anti-cancer drug against hepatocellular carcinoma. Hepatology, 2011, 54(3), 857-867.
62. Abdullaev, F. I.; Espinosa-Aguirre, J. J. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev., 2004, 28 (6), 426-432.
63. Samarghandian, S.; Boskabady, M. H.; Davoodi, S. Use of in vitro assays to assess the potential antiproliferative and cytotoxic effects of saffron (Crocus sativus L.) in human lung cancer cell line. Pharmacogn. Mag., 2011, 6 (24), 309-314.
64. Samarghandian, S.; Tavakkol Afshari, J.; Davoodi, S. Suppression of pulmonary tumor promotion and induction of apoptosis by Crocus sativus L. extraction. Appl. Biochem. Biotechnol., 2010, 164 (2), 238-247.
65. Bakshi, H.; Sam, S.; Rozati, R.; Sultan, P.; Islam, T.; Rathore, B.; Lone, Z.; Sharma, M.; Triphati, J.; Saxena, R. C. DNA fragmentation and cell cycle arrest: a hallmark of apoptosis induced by crocin from kashmiri saffron in a human pancreatic cancer cell line. Asian Pac. J. Cancer Prev., 2010, 11 (3), 675-679.
66. Das, I.; Das, S.; Saha, T. Saffron suppresses oxidative stress in DMBA-induced skin carcinoma: A histopathological study. Acta Histochem., 2010, 112 (4), 317-327.
67. Aung, H. H.; Wang, C. Z.; Ni, M.; Fishbein, A.; Mehendale, S. R.; Xie, J. T.; Shoyama, C. Y.; Yuan, C. S. Crocin from Crocus sativus possesses significant anti-proliferation effects on human colorectal cancer cells. Exp. Oncol., 2007, 29 (3), 175-180.
68. Chryssanthi, D. G.; Dedes, P. G.; Karamanos, N. K.; Cordopatis, P.; Lamari, F. N. Crocetin inhibits invasiveness of MDA-MB-231 breast cancer cells via downregulation of matrix metallo- proteinases. Planta Med., 2011, 77 (2), 146-151.
69. Bathaie, S. Z.; Mousavi, S. Z. New applications and mechanisms of action of saffron and its important ingredients. Crit. Rev. Food Sci. Nutr., 2010, 50 (8), 761-786.
70. Nam, K. N.; Park, Y. M.; Jung, H. J.; Lee, J. Y.; Min, B. D.; Park, S. U.; Jung, W. S.; Cho, K. H.; Park, J. H.; Kang, I.; Hong, J. W.; Lee, E. H. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur. J. Pharmacol., 2010, 648 (1-3), 110-116.
71. Kim, J. M.; Kim, J. S.; Yoo, H.; Choung, M. G.; Sung, M. K. Effects of black soybean [Glycine max (L.) Merr.] seed coats and its anthocyanidins on colonic inflammation and cell proliferation in vitro and in vivo. J. Agric. Food Chem., 2008, 56 (18), 8427-8433.
72. Lim, T. G.; Kwon, J. Y.; Kim, J.; Song, N. R.; Lee, K. M.; Heo, Y. S.; Lee, H. J.; Lee, K. W. Cyanidin-3-glucoside suppresses B[a]PDE-induced cyclooxygenase-2 expression by directly inhibiting Fyn kinase activity. Biochem. Pharmacol., 2011, 82 (2), 167-174.
73. Xu, M.; Bower, K. A.; Wang, S.; Frank, J. A.; Chen, G.; Ding, M.; Wang, S.; Shi, X.; Ke, Z.; Luo, J. Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2. Mol. Cancer, 2011, 9, 285.
74. Zikri, N. N.; Riedl, K. M.; Wang, L. S.; Lechner, J.; Schwartz, S. J.; Stoner, G. D. Black raspberry components inhibit proliferation, induce apoptosis, and modulate gene expression in rat esophageal epithelial cells. Nutr. Cancer, 2009, 61 (6), 816-826.
75. Kim, J. E.; Kwon, J. Y.; Seo, S. K.; Son, J. E.; Jung, S. K.; Min, S. Y.; Hwang, M. K.; Heo, Y. S.; Lee, K. W.; Lee, H. J. Cyanidin suppresses ultraviolet B-induced COX-2 expression in epidermal cells by targeting MKK4, MEK1, and Raf-1. Biochem. Pharmacol., 2010, 79 (10), 1473-1482.
76. Dreiseitel, A.; Oosterhuis, B.; Vukman, K. V.; Schreier, P.; Oehme, A.; Locher, S.; Hajak, G.; Sand, P. G. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br. J. Pharmacol., 2009, 158 (8), 1942-1950.
77. Kim, Y. S.; Milner, J. A. Targets for indole-3-carbinol in cancer prevention. J. Nutr. Biochem., 2005, 16 (2), 65-73.
78. Qian, X.; Melkamu, T.; Upadhyaya, P.; Kassie, F. Indole-3- carbinol inhibited tobacco smoke carcinogen-induced lung adenocarcinoma in A/J mice when administered during the post- initiation or progression phase of lung tumorigenesis. Cancer Lett., 2011, 311(1), 57-65.
79. Acharya, A.; Das, I.; Singh, S.; Saha, T. Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric., 2010, 2 (2), 166-177.
80. Bradlow, H. L.; Zeligs, M. A. Diindolylmethane (DIM) spontaneously forms from indole-3-carbinol (I3C) during cell culture experiments. In Vivo, 2010, 24 (4), 387-391.
81. Banerjee, S.; Kong, D.; Wang, Z.; Bao, B.; Hillman, G. G.; Sarkar, F. H. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): From bench to clinic. Mutat. Res., 2011, 728(1-2), 47-66.
82. Saw, C. L.; Cintron, M.; Wu, T. Y.; Guo, Y.; Huang, Y.; Jeong, W. S.; Kong, A. N. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: Induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm. Drug Dispos., 2011, 32 (5), 289-300.
83. Lubet, R. A.; Heckman, B. M.; De Flora, S. L.; Steele, V. E.; Crowell, J. A.; Juliana, M. M.; Grubbs, C. J. Effects of 5,6- benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: Is DIM a substitute for I3C? Oncol. Rep., 2011, 26 (3), 731-736.
84. Wang, T. T.; Schoene, N. W.; Milner, J. A.; Kim, Y. S. Broccoli- derived phytochemicals indole-3-carbinol and 3,3'-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: Comparison with other cancer preventive phytochemicals. Mol. Carcinog., 2011, 51(3), 244-256.
85. Das, A.; Banik, N. L.; Ray, S. K. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. Cancer, 2010, 116 (1), 164-176.
86. Hsieh, T. C.; Wu, J. M. Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res., 2009, 29 (10), 4025-4032.
87. Qiao, Y.; Cao, J.; Xie, L.; Shi, X. Cell growth inhibition and gene expression regulation (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res., 2009, 32 (9), 1309-1315.
88. Philips, B. J.; Coyle, C. H.; Morrisroe, S. N.; Chancellor, M. B.; Yoshimura, N. Induction of apoptosis in human bladder cancer cells by green tea catechins. Biomed. Res., 2009, 30 (4), 207-215.
89. Yang, C. S.; Lambert, J. D.; Ju, J.; Lu, G.; Sang, S. Tea and cancer prevention: molecular mechanisms and human relevance. Toxicol. Appl. Pharmacol., 2007, 224 (3), 265-273.
90. Yang, C. S.; Lambert, J. D.; Hou, Z.; Ju, J.; Lu, G.; Hao, X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog., 2006, 45 (6), 431-435.
91. Lambert, J. D.; Yang, C. S. Mechanisms of cancer prevention by tea constituents. J. Nutr., 2003, 133 (10), 3262S-3267S.
92. Leone, M.; Zhai, D.; Sareth, S.; Kitada, S.; Reed, J. C.; Pellecchia, M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res., 2003, 63 (23), 8118-8121.
93. Cherbonnel-Lasserre, C.; Dosanjh, M. K. Suppression of apoptosis by overexpression of Bcl-2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. Biochimie, 1997, 79 (9-10), 613-617.
94. Shimizu, M.; Shirakami, Y.; Sakai, H.; Adachi, S.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. (Phila), 2008, 1 (4), 298-304.
95. Adachi, S.; Shimizu, M.; Shirakami, Y.; Yamauchi, J.; Natsume, H.; Matsushima-Nishiwaki, R.; To, S.; Weinstein, I. B.; Moriwaki, H.; Kozawa, O. (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis, 2009, 30 (9), 1544-1552.
96. Larsen, C. A.; Dashwood, R. H. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch. Biochem. Biophys., 2010, 501 (1), 52-57.
97. Chen, C.; Shen, G.; Hebbar, V.; Hu, R.; Owuor, E. D.; Kong, A. N. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. Carcinogenesis, 2003, 24 (8), 1369-1378.
98. Nair, S.; Hebbar, V.; Shen, G.; Gopalakrishnan, A.; Khor, T. O.; Yu, S.; Xu, C.; Kong, A. N. Synergistic effects of a combination of dietary factors sulforaphane and (-) epigallocatechin-3-gallate in HT-29 AP-1 human colon carcinoma cells. Pharm. Res., 2008, 25 (2), 387-399.
99. Shen, G.; Xu, C.; Hu, R.; Jain, M. R.; Nair, S.; Lin, W.; Yang, C. S.; Chan, J. Y.; Kong, A. N. Comparison of (-)-epigallocatechin-3- gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res., 2005, 22 (11), 1805-1820.
100. Gabor, M.; Eperjessy, E. Antibacterial effect of fisetin and fisetinidin. Nature, 1966, 212 (5067), 1273.
101. Maher, P.; Dargusch, R.; Ehren, J. L.; Okada, S.; Sharma, K.; Schubert, D. Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes. PLoS One, 2011, 6 (6), e21226.
102. Arai, Y.; Watanabe, S.; Kimira, M.; Shimoi, K.; Mochizuki, R.; Kinae, N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J. Nutr., 2000, 130 (9), 2243-2250.
103. Howitz, K. T.; Bitterman, K. J.; Cohen, H. Y.; Lamming, D. W.; Lavu, S.; Wood, J. G.; Zipkin, R. E.; Chung, P.; Kisielewski, A.; Zhang, L. L.; Scherer, B.; Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425 (6954), 191-196.
104. Wood, J. G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S. L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430 (7000), 686-689.
105. Geraets, L.; Haegens, A.; Brauers, K.; Haydock, J. A.; Vernooy, J. H.; Wouters, E. F.; Bast, A.; Hageman, G. J. Inhibition of LPS- induced pulmonary inflammation by specific flavonoids. Biochem. Biophys. Res. Commun., 2009, 382 (3), 598-603.
106. Lim do, Y.; Park, J. H. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am. J. Physiol. Gastrointest. Liver Physiol, 2009, 296 (5), G1060-1068.
107. Williams, R. J.; Spencer, J. P.; Rice-Evans, C. Flavonoids: antioxidants or signalling molecules? Free Radic. Biol. Med., 2004, 36 (7), 838-849.
108. Hanneken, A.; Lin, F. F.; Johnson, J.; Maher, P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest. Ophthalmol. Vis. Sci., 2006, 47 (7), 3164-3177.
109. Lee, S. E.; Jeong, S. I.; Yang, H.; Park, C. S.; Jin, Y. H.; Park, Y. S. Fisetin induces Nrf2-mediated HO-1 expression through PKC- delta and p38 in human umbilical vein endothelial cells. J. Cell Biochem., 2011, 112(9), 2352-2360.
110. Khan, N.; Afaq, F.; Khusro, F. H.; Adhami, V. M.; Suh, Y.; Mukhtar, H. Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin. Int. J. Cancer, 2011, 130(7), 1695-1705.
111. Teiten, M. H.; Gaascht, F.; Dicato, M.; Diederich, M. Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents. Curr. Pharm. Biotechnol., 2011, 13(1), 245-254.
112. Syed, D. N.; Afaq, F.; Maddodi, N.; Johnson, J. J.; Sarfaraz, S.; Ahmad, A.; Setaluri, V.; Mukhtar, H. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/beta-catenin signaling and decreased Mitf levels. J. Invest. Dermatol., 2011, 131 (6), 1291-1299.
113. Liao, Y. C.; Shih, Y. W.; Chao, C. H.; Lee, X. Y.; Chiang, T. A. Involvement of the ERK signaling pathway in fisetin reduces invasion and migration in the human lung cancer cell line A549. J. Agric. Food Chem., 2009, 57 (19), 8933-8941.
114. Angelini, A.; Di Ilio, C.; Castellani, M. L.; Conti, P.; Cuccurullo, F. Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J. Biol. Regul. Homeost. Agents, 2010, 24 (2), 197-205.
115. Markovits, J.; Linassier, C.; Fosse, P.; Couprie, J.; Pierre, J.; Jacquemin-Sablon, A.; Saucier, J. M.; Le Pecq, J. B.; Larsen, A. K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res., 1989, 49 (18), 5111-5117.
116. Lopez-Lazaro, M.; Willmore, E.; Austin, C. A. Cells lacking DNA topoisomerase II beta are resistant to genistein. J. Nat. Prod., 2007, 70 (5), 763-767.
117. Wang, W.; Bringe, N. A.; Berhow, M. A.; Gonzalez de Mejia, E. beta-Conglycinins among sources of bioactives in hydrolysates of different soybean varieties that inhibit leukemia cells in vitro. J. Agric. Food Chem., 2008, 56 (11), 4012-4020.
118. Sanchez, Y.; Amran, D.; de Blas, E.; Aller, P. Regulation of genistein-induced differentiation in human acute myeloid leukaemia cells (HL60, NB4) Protein kinase modulation and reactive oxygen species generation. Biochem. Pharmacol., 2009, 77 (3), 384-396.
119. Raynal, N. J.; Momparler, L.; Charbonneau, M.; Momparler, R. L. Antileukemic activity of genistein, a major isoflavone present in soy products. J. Nat. Prod., 2008, 71 (1), 3-7.
120. Yamasaki, M.; Fujita, S.; Ishiyama, E.; Mukai, A.; Madhyastha, H.; Sakakibara, Y.; Suiko, M.; Hatakeyama, K.; Nemoto, T.; Morishita, K.; Kataoka, H.; Tsubouchi, H.; Nishiyama, K. Soyderived isoflavones inhibit the growth of adult T-cell leukemia cells in vitro and in vivo. Cancer Sci., 2007, 98 (11), 1740-1746.
121. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; van der Saag, P. T.; van der Burg, B.; Gustafsson, J. A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology, 1998, 139 (10), 4252-4263.
122. Ju, Y. H.; Allred, K. F.; Allred, C. D.; Helferich, W. G. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis, 2006, 27 (6), 1292-1299.
123. Yang, X.; Yang, S.; McKimmey, C.; Liu, B.; Edgerton, S. M.; Bales, W.; Archer, L. T.; Thor, A. D. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis, 2010, 31 (4), 695-702.
124. Seibel, J.; Molzberger, A. F.; Hertrampf, T.; Laudenbach-Leschowski, U.; Diel, P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur. J. Nutr., 2009, 48 (4), 213-220.
125. Gopalakrishnan, A.; Xu, C. J.; Nair, S. S.; Chen, C.; Hebbar, V.; Kong, A. N. Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. Arch. Pharm. Res., 2006, 29 (8), 633-644.
126. Jeong, C. H.; Bode, A. M.; Pugliese, A.; Cho, Y. Y.; Kim, H. G.; Shim, J. H.; Jeon, Y. J.; Li, H.; Jiang, H.; Dong, Z. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res., 2009, 69 (13), 5584-5591.
127. Lee, H. S.; Seo, E. Y.; Kang, N. E.; Kim, W. K. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J. Nutr. Biochem., 2008, 19 (5), 313-319.
128. Rhode, J.; Fogoros, S.; Zick, S.; Wahl, H.; Griffith, K. A.; Huang, J.; Liu, J. R. Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement. Altern. Med., 2007, 7 44.
129. Park, Y. J.; Wen, J.; Bang, S.; Park, S. W.; Song, S. Y. [6]- Gingerol induces cell cycle arrest and cell death of mutant p53- expressing pancreatic cancer cells. Yonsei Med. J., 2006, 47 (5), 688-697.
130. Oyagbemi, A. A.; Saba, A. B.; Azeez, O. I. Molecular targets of [6]-gingerol: Its potential roles in cancer chemoprevention. Biofactors, 2010, 36 (3), 169-178.
131. Zeng, H. L.; Han, X. A.; Gu, C.; Zhu, H. Y.; Huang, X. S.; Gu, J. Q.; Zhong, Q.; Liu, G. J.; Ming, W. J.; Cai, X. N. [Reactive oxygen species and mitochondrial membrane potential changes in leukemia cells during 6-gingerol induced apoptosis]. Zhong Yao Cai, 2010, 33 (4), 584-587.
132. Weng, C. J.; Wu, C. F.; Huang, H. W.; Ho, C. T.; Yen, G. C. Antiinvasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells. Mol. Nutr. Food Res., 2010, 54 (11), 1618-1627.
133. Wu, H.; Hsieh, M. C.; Lo, C. Y.; Liu, C. B.; Sang, S.; Ho, C. T.; Pan, M. H. 6-Shogaol is more effective than 6-gingerol and curcumin in inhibiting 12-O-tetradecanoylphorbol 13-acetate- induced tumor promotion in mice. Mol. Nutr. Food Res., 2010, 54 (9), 1296-1306.
134. Park, J. S.; Rho, H. S.; Kim, D. H.; Chang, I. S. Enzymatic preparation of kaempferol from green tea seed and its antioxidant activity. J. Agric. Food Chem., 2006, 54 (8), 2951-2956.
135. Nothlings, U.; Murphy, S. P.; Wilkens, L. R.; Henderson, B. E.; Kolonel, L. N. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am. J. Epidemiol., 2007, 166 (8), 924-931.
136. Cui, Y.; Morgenstern, H.; Greenland, S.; Tashkin, D. P.; Mao, J. T.; Cai, L.; Cozen, W.; Mack, T. M.; Lu, Q. Y.; Zhang, Z. F. Dietary flavonoid intake and lung cancer--a population-based casecontrol study. Cancer, 2008, 112 (10), 2241-2248.
137. Gacche, R. N.; Shegokar, H. D.; Gond, D. S.; Yang, Z.; Jadhav, A. D. Evaluation of Selected Flavonoids as Antiangiogenic, Anticancer, and Radical Scavenging Agents: An Experimental and In Silico Analysis. Cell Biochem. Biophys., 2011, 61(3), 651-663.
138. Calderon-Montano, J. M.; Burgos-Moron, E.; Perez-Guerrero, C.; Lopez-Lazaro, M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem., 2011, 11 (4), 298-344.
139. Bigovic, D.; Savikin, K.; Jankovic, T.; Menkovic, N.; Zdunic, G.; Stanojkovic, T.; Djuric, Z. Antiradical and cytotoxic activity of different Helichrysum plicatum flower extracts. Nat. Prod. Commun., 2011, 6 (6), 819-822.
140. To, K. K.; Yu, L.; Liu, S.; Fu, J.; Cho, C. H. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol. Carcinog., 2011, 51(6), 449-464.
141. Luo, H.; Rankin, G. O.; Li, Z.; Depriest, L.; Chen, Y. C. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem., 2011, 128 (2), 513-519.
142. Yang, J. H.; Kondratyuk, T. P.; Jermihov, K. C.; Marler, L. E.; Qiu, X.; Choi, Y.; Cao, H.; Yu, R.; Sturdy, M.; Huang, R.; Liu, Y.; Wang, L. Q.; Mesecar, A. D.; van Breemen, R. B.; Pezzuto, J. M.; Fong, H. H.; Chen, Y. G.; Zhang, H. J. Bioactive compounds from the fern Lepisorus contortus. J. Nat. Prod., 2011, 74 (2), 129-136.
143. Niestroy, J.; Barbara, A.; Herbst, K.; Rode, S.; van Liempt, M.; Roos, P. H. Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2. Toxicol. In Vitro, 2011, 25 (3), 671-683.
144. Barve, A.; Chen, C.; Hebbar, V.; Desiderio, J.; Saw, C. L.; Kong, A. N. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm. Drug Dispos., 2009, 30 (7), 356-365.
145. An, G.; Gallegos, J.; Morris, M. E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab. Dispos., 2011, 39 (3), 426-432.
146. Giovannucci, E.; Ascherio, A.; Rimm, E. B.; Stampfer, M. J.; Colditz, G. A.; Willett, W. C. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl. Cancer. Inst., 1995, 87 (23), 1767-1776.
147. Levy, J.; Bosin, E.; Feldman, B.; Giat, Y.; Miinster, A.; Danilenko, M.; Sharoni, Y. Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene. Nutr. Cancer, 1995, 24 (3), 257-266.
148. Nahum, A.; Hirsch, K.; Danilenko, M.; Watts, C. K.; Prall, O. W.; Levy, J.; Sharoni, Y. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene, 2001, 20 (26), 3428-3436.
149. Narisawa, T.; Fukaura, Y.; Hasebe, M.; Ito, M.; Aizawa, R.; Murakoshi, M.; Uemura, S.; Khachik, F.; Nishino, H. Inhibitory effects of natural carotenoids, alpha-carotene, beta-carotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats. Cancer Lett, 1996, 107 (1), 137-142.
150. Canene-Adams, K.; Lindshield, B. L.; Wang, S.; Jeffery, E. H.; Clinton, S. K.; Erdman, J. W., Jr. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res, 2007, 67 (2), 836-843.
151. Hahm, E. R.; Singh, S. V. Bim contributes to phenethyl isothiocyanate-induced apoptosis in breast cancer cells. Mol Carcinog, 2011, 51(6), 465-474.
152. Moon, Y. J.; Brazeau, D. A.; Morris, M. E. Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells. Evid. Based Complement. Alternat. Med., 2011, 2011.
153. Yan, H.; Zhu, Y.; Liu, B.; Wu, H.; Li, Y.; Wu, X.; Zhou, Q.; Xu, K. Mitogen-activated protein kinase mediates the apoptosis of highly metastatic human non-small cell lung cancer cells induced by isothiocyanates. Br. J. Nutr., 2011, 106(12), 1779-1791.
154. Huong, L. D.; Shim, J. H.; Choi, K. H.; Shin, J. A.; Choi, E. S.; Kim, H. S.; Lee, S. J.; Kim, S. J.; Cho, N. P.; Cho, S. D. Effect of beta-Phenylethyl Isothiocyanate from Cruciferous Vegetables on Growth Inhibition and Apoptosis of Cervical Cancer Cells through the Induction of Death Receptors 4 and 5. J. Agric. Food Chem., 2011, 59(15), 8124-8131.
155. Wang, X.; Govind, S.; Sajankila, S. P.; Mi, L.; Roy, R.; Chung, F. L. Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol. Nutr. Food Res., 2011, 55(10), 1572-1581.
156. Wu, C. L.; Huang, A. C.; Yang, J. S.; Liao, C. L.; Lu, H. F.; Chou, S. T.; Ma, C. Y.; Hsia, T. C.; Ko, Y. C.; Chung, J. G. Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)- mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of caspase-3, mitochondria dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2 OS cells. J. Orthop. Res., 2011, 29 (8), 1199-1209.
157. Xiao, D.; Powolny, A. A.; Moura, M. B.; Kelley, E. E.; Bommareddy, A.; Kim, S. H.; Hahm, E. R.; Normolle, D.; Van Houten, B.; Singh, S. V. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species- mediated death of human prostate cancer cells. J. Biol. Chem., 2010, 285 (34), 26558-26569.
158. Hwang, E. S.; Lee, H. J. Effects of phenylethyl isothiocyanate and its metabolite on cell-cycle arrest and apoptosis in LNCaP human prostate cancer cells. Int. J. Food Sci. Nutr., 2010, 61 (3), 324-336.
159. Powolny, A. A.; Singh, S. V. Differential response of normal (PrEC) and cancerous human prostate cells (PC-3) to phenethyl isothiocyanate-mediated changes in expression of antioxidant defense genes. Pharm. Res., 2010, 27 (12), 2766-2775.
160. Jakubikova, J.; Cervi, D.; Ooi, M.; Kim, K.; Nahar, S.; Klippel, S.; Cholujova, D.; Leiba, M.; Daley, J. F.; Delmore, J.; Negri, J.; Blotta, S.; McMillin, D.; Hideshima, T.; Richardson, P.; Sedlak, J.; Anderson, K.; Mitsiades, C. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and PEITC in multiple myeloma. Haematologica., 2011, 96(8), 1170-1179.
161. Tang, N. Y.; Huang, Y. T.; Yu, C. S.; Ko, Y. C.; Wu, S. H.; Ji, B. C.; Yang, J. S.; Yang, J. L.; Hsia, T. C.; Chen, Y. Y.; Chung, J. G. Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells. Anticancer Res., 2011, 31 (5), 1691-1702.
162. Gao, N.; Budhraja, A.; Cheng, S.; Liu, E. H.; Chen, J.; Yang, Z.; Chen, D.; Zhang, Z.; Shi, X. Phenethyl isothiocyanate exhibits antileukemic activity in vitro and in vivo by inactivation of Akt and activation of JNK pathways. Cell Death Dis., 2011, 2 e140.
163. Wang, X.; Di Pasqua, A. J.; Govind, S.; McCracken, E.; Hong, C.; Mi, L.; Mao, Y.; Wu, J. Y.; Tomita, Y.; Woodrick, J. C.; Fine, R. L.; Chung, F. L. Selective Depletion of Mutant p53 by Cancer Chemopreventive Isothiocyanates and Their Structure-Activity Relationships. J. Med. Chem., 2011, 54(3), 809-816.
164. Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275 (5297), 218-220.
165. Boocock, D. J.; Faust, G. E.; Patel, K. R.; Schinas, A. M.; Brown, V. A.; Ducharme, M. P.; Booth, T. D.; Crowell, J. A.; Perloff, M.; Gescher, A. J.; Steward, W. P.; Brenner, D. E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev, 2007, 16 (6), 1246-1252.
166. Niles, R. M.; Cook, C. P.; Meadows, G. G.; Fu, Y. M.; McLaughlin, J. L.; Rankin, G. O. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr, 2006, 136 (10), 2542-2546.
167. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res., 2005, 49 (5), 482-494.
168. Kim, K. H.; Back, J. H.; Zhu, Y.; Arbesman, J.; Athar, M.; Kopelovich, L.; Kim, A. L.; Bickers, D. R. Resveratrol targets transforming growth factor-beta2 signaling to block UV-induced tumor progression. J. Invest. Dermatol., 2011, 131 (1), 195-202.
169. Nichols, J. A.; Katiyar, S. K. Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch. Dermatol. Res., 2010, 302 (2), 71-83.
170. Li, Z. G.; Hong, T.; Shimada, Y.; Komoto, I.; Kawabe, A.; Ding, Y.; Kaganoi, J.; Hashimoto, Y.; Imamura, M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis, 2002, 23 (9), 1531-1536.
171. Wu, H.; Liang, X.; Fang, Y.; Qin, X.; Zhang, Y.; Liu, J. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed. Pharmacother., 2008, 62 (9), 613-621.
172. Sanchez-Fidalgo, S.; Cardeno, A.; Villegas, I.; Talero, E.; de la Lastra, C. A. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur. J. Pharmacol., 2010, 633 (1-3), 78-84.
173. Hope, C.; Planutis, K.; Planutiene, M.; Moyer, M. P.; Johal, K. S.; Woo, J.; Santoso, C.; Hanson, J. A.; Holcombe, R. F. Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol. Nutr. Food Res., 2008, 52 Suppl 1 S52-61.
174. Fujimoto, A.; Sakanashi, Y.; Matsui, H.; Oyama, T.; Nishimura, Y.; Masuda, T.; Oyama, Y. Cytometric analysis of cytotoxicity of polyphenols and related phenolics to rat thymocytes: potent cytotoxicity of resveratrol to normal cells. Basic Clin. Pharmacol. Toxicol., 2009, 104 (6), 455-462.
175. Hebbar, V.; Shen, G.; Hu, R.; Kim, B. R.; Chen, C.; Korytko, P. J.; Crowell, J. A.; Levine, B. S.; Kong, A. N. Toxicogenomics of resveratrol in rat liver. Life Sci., 2005, 76 (20), 2299-2314.
176. Xu, Y.; Xu, G.; Liu, L.; Xu, D.; Liu, J. Anti-invasion effect of rosmarinic acid via the extracellular signal-regulated kinase and oxidation-reduction pathway in Ls174-T cells. J. Cell Biochem., 2010, 111 (2), 370-379.
177. Xu, Y.; Jiang, Z.; Ji, G.; Liu, J. Inhibition of bone metastasis from breast carcinoma by rosmarinic acid. Planta Med., 2010, 76 (10), 956-962.
178. Moon, D. O.; Kim, M. O.; Lee, J. D.; Choi, Y. H.; Kim, G. Y. Rosmarinic acid sensitizes cell death through suppression of TNF- alpha-induced NF-kappaB activation and ROS generation in human leukemia U937 cells. Cancer Lett., 2010, 288 (2), 183-191.
179. Scheckel, K. A.; Degner, S. C.; Romagnolo, D. F. Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer and nonmalignant cell lines. J. Nutr., 2008, 138 (11), 2098-2105.
180. Li, Y.; Zhang, T.; Korkaya, H.; Liu, S.; Lee, H. F.; Newman, B.; Yu, Y.; Clouthier, S. G.; Schwartz, S. J.; Wicha, M. S.; Sun, D. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res., 2010, 16 (9), 2580-2590.
181. Talalay, P.; Fahey, J. W.; Healy, Z. R.; Wehage, S. L.; Benedict, A. L.; Min, C.; Dinkova-Kostova, A. T. Sulforaphane mobilizes cellular defenses that protect skin against damage by UV radiation. Proc. Natl. Acad. Sci. U S A, 2007, 104 (44), 17500-17505.
182. Dashwood, R. H.; Ho, E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin. Cancer Biol., 2007, 17 (5), 363-369.
183. Shen, G.; Khor, T. O.; Hu, R.; Yu, S.; Nair, S.; Ho, C. T.; Reddy, B. S.; Huang, M. T.; Newmark, H. L.; Kong, A. N. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res., 2007, 67 (20), 9937-9944.
184. Rudolf, E.; Andelova, H.; Cervinka, M. Activation of several concurrent proapoptic pathways by sulforaphane in human colon cancer cells SW620. Food Chem. Toxicol., 2009, 47 (9), 2366-2373.
185. Rudolf, E.; Cervinka, M. Sulforaphane induces cytotoxicity and lysosome- and mitochondria-dependent cell death in colon cancer cells with deleted p53. Toxicol. In Vitro, 2011, 25(7), 1302-1309.
186. Jeong, W. S.; Keum, Y. S.; Chen, C.; Jain, M. R.; Shen, G.; Kim, J. H.; Li, W.; Kong, A. N. Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J. Biochem. Mol. Biol., 2005, 38 (2), 167-176.
187. Xu, C.; Shen, G.; Chen, C.; Gelinas, C.; Kong, A. N. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene, 2005, 24 (28), 4486-4495.
188. Li, W.; Jain, M. R.; Chen, C.; Yue, X.; Hebbar, V.; Zhou, R.; Kong, A. N. Nrf2 Possesses a redox-insensitive nuclear export signal overlapping with the leucine zipper motif. J. Biol. Chem., 2005, 280 (31), 28430-28438.
189. Keum, Y. S.; Yu, S.; Chang, P. P.; Yuan, X.; Kim, J. H.; Xu, C.; Han, J.; Agarwal, A.; Kong, A. N. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res., 2006, 66 (17), 8804-8813.
190. Lin, W.; Wu, R. T.; Wu, T.; Khor, T. O.; Wang, H.; Kong, A. N. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem. Pharmacol., 2008, 76 (8), 967-973.
191. Hu, R.; Xu, C.; Shen, G.; Jain, M. R.; Khor, T. O.; Gopalkrishnan, A.; Lin, W.; Reddy, B.; Chan, J. Y.; Kong, A. N. Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett., 2006, 243 (2), 170-192.
192. Hu, R.; Khor, T. O.; Shen, G.; Jeong, W. S.; Hebbar, V.; Chen, C.; Xu, C.; Reddy, B.; Chada, K.; Kong, A. N. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis, 2006, 27 (10), 2038-2046.
193. Xu, C.; Huang, M. T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T. O.; Conney, A. H.; Kong, A. N. Inhibition of 7,12-dimethylbenz (a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res., 2006, 66 (16), 8293-8296.
194. Khor, T. O.; Hu, R.; Shen, G.; Jeong, W. S.; Hebbar, V.; Chen, C.; Xu, C.; Nair, S.; Reddy, B.; Chada, K.; Kong, A. N. Pharmacogenomics of cancer chemopreventive isothiocyanate compound sulforaphane in the intestinal polyps of ApcMin/+ mice. Biopharm. Drug Dispos., 2006, 27 (9), 407-420.
195. Saw, C. L.; Huang, M. T.; Liu, Y.; Khor, T. O.; Conney, A. H.; Kong, A. N. Impact of Nrf2 on UVB-induced skin inflammation/ photoprotection and photoprotective effect of sulforaphane. Mol. Carcinog., 2011, 50(6), 479-486.
196. Keum, Y. S.; Khor, T. O.; Lin, W.; Shen, G.; Kwon, K. H.; Barve, A.; Li, W.; Kong, A. N. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm. Res., 2009, 26 (10), 2324-2331.
197. Phillips, D. R.; Rasbery, J. M.; Bartel, B.; Matsuda, S. P. Biosynthetic diversity in plant triterpene cyclization. Curr. Opin. Plant Biol., 2006, 9 (3), 305-314.
198. Tholl, D. Terpene synthases and the regulation, diversity and biological roles of terpene metabolism. Curr. Opin. Plant Biol., 2006, 9 (3), 297-304.
199. Chidambara Murthy, K. N.; Jayaprakasha, G. K.; Patil, B. S. Apoptosis mediated cytotoxicity of citrus obacunone in human pancreatic cancer cells. Toxicol. In Vitro, 2011, 25 (4), 859-867.
200. Buyru, N.; Tezol, A.; Yosunkaya-Fenerci, E.; Dalay, N. Vitamin D receptor gene polymorphisms in breast cancer. Exp. Mol. Med., 2003, 35 (6), 550-555.
201. Gorham, E. D.; Garland, C. F.; Garland, F. C.; Grant, W. B.; Mohr, S. B.; Lipkin, M.; Newmark, H. L.; Giovannucci, E.; Wei, M.; Holick, M. F. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am. J. Prev. Med., 2007, 32 (3), 210-216.
202. Garland, C. F.; Mohr, S. B.; Gorham, E. D.; Grant, W. B.; Garland, F. C. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am. J. Prev. Med., 2006, 31 (6), 512-514.
203. Skinner, H. G.; Michaud, D. S.; Giovannucci, E.; Willett, W. C.; Colditz, G. A.; Fuchs, C. S. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev., 2006, 15 (9), 1688-1695.
204. Chen, W. Y.; Bertone-Johnson, E. R.; Hunter, D. J.; Willett, W. C.; Hankinson, S. E. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol. Biomarkers Prev., 2005, 14 (10), 2335-2339.
205. Kovalenko, P. L.; Zhang, Z.; Yu, J. G.; Li, Y.; Clinton, S. K.; Fleet, J. C. Dietary vitamin D and vitamin D receptor level modulate epithelial cell proliferation and apoptosis in the prostate. Cancer Prev. Res. (Phila), 2011, 4(10), 1617-1625.
206. Stefanska, B.; Salame, P.; Bednarek, A.; Fabianowska-Majewska, K. Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br. J. Nutr., 2012, 107(6), 781-790.
207. Buttigliero, C.; Monagheddu, C.; Petroni, P.; Saini, A.; Dogliotti, L.; Ciccone, G.; Berruti, A. Prognostic Role of Vitamin D Status and Efficacy of Vitamin D Supplementation in Cancer Patients: A Systematic Review. Oncologist, 2011, 16(9), 1215-1227.
208. Dorjgochoo, T.; Delahanty, R.; Lu, W.; Long, J. R.; Cai, Q.; Zheng, Y.; Gu, K.; Gao, Y. T.; Zheng, W.; Shu, X. O. Common genetic variants in the vitamin D pathway including genome-wide associated variants are not associated with breast cancer risk among Chinese women. Cancer Epidemiol. Biomarkers Prev., 2011, 20(10), 2313-2316.
209. Clipp, S. L.; Burke, A.; Hoffman-Bolton, J.; Alani, R.; Liegeois, N. J.; Alberg, A. J. Sun-seeking behavior to increase cutaneous vitamin D synthesis: when prevention messages conflict. Public Health Rep., 2011, 126 (4), 533-539.
210. Barnett, C. M.; Beer, T. M. Prostate cancer and vitamin d: what does the evidence really suggest? Urol. Clin. North Am., 2011, 38 (3), 333-342.
211. Wada, S. Cancer Preventive Effects of Vitamin E. Curr. Pharm. Biotechnol., 2011, 13(1), 156-164.
212. Chen, Z. L.; Tao, J.; Yang, J.; Yuan, Z. L.; Liu, X. H.; Jin, M.; Shen, Z. Q.; Wang, L.; Li, H. F.; Qiu, Z. G.; Wang, J. F.; Wang, X. W.; Li, J. W. Vitamin E Modulates Cigarette Smoke Extract- induced Cell Apoptosis in Mouse Embryonic Cells. Int. J. Biol. Sci., 2011, 7 (7), 927-936.
213. Nesaretnam, K.; Meganathan, P. Tocotrienols: inflammation and cancer. Ann. N Y Acad. Sci., 2011, 1229 (1), 18-22.
214. Fulan, H.; Changxing, J.; Baina, W. Y.; Wencui, Z.; Chunqing, L.; Fan, W.; Dandan, L.; Dianjun, S.; Tong, W.; Da, P.; Yashuang, Z. Retinol, vitamins A, C, and E and breast cancer risk: a meta- analysis and meta-regression. Cancer Causes Control, 2011, 22(10), 1383-1396.
215. Shin-Kang, S.; Ramsauer, V. P.; Lightner, J.; Chakraborty, K.; Stone, W.; Campbell, S.; Reddy, S. A.; Krishnan, K. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. Free Radic. Biol. Med., 2011, 51 (6), 1164-1174.
216. Sylvester, P. W.; Wali, V. B.; Bachawal, S. V.; Shirode, A. B.; Ayoub, N. M.; Akl, M. R. Tocotrienol combination therapy results in synergistic anticancer response. Front. Biosci., 2011, 17 3183-3195.
217. Li-Weber, M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett., 2010, Epub ahead of print, August 2.
218. Kong, A. N.; Yu, R.; Lei, W.; Mandlekar, S.; Tan, T. H.; Ucker, D. S. Differential activation of MAPK and ICE/Ced-3 protease in chemical-induced apoptosis. The role of oxidative stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene expression and survival or activation of caspases leading to apoptosis. Restor. Neurol. Neurosci., 1998, 12 (2-3), 63-70.
219. Lemasters, J. J.; Theruvath, T. P.; Zhong, Z.; Nieminen, A. L. Mitochondrial calcium and the permeability transition in cell death. Biochim. Biophys. Acta, 2009, 1787 (11), 1395-1401.
220. Fesik, S. W.; Shi, Y. Structural biology. Controlling the caspases. Science, 2001, 294 (5546), 1477-1478.
221. Dejean, L. M.; Martinez-Caballero, S.; Kinnally, K. W. Is MAC the knife that cuts cytochrome c from mitochondria during apoptosis? Cell Death Differ., 2006, 13 (8), 1387-1395.
222. Dejean, L. M.; Martinez-Caballero, S.; Manon, S.; Kinnally, K. W. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochim. Biophys. Acta, 2006, 1762 (2), 191-201.
223. Wajant, H. The Fas signaling pathway: more than a paradigm. Science, 2002, 296 (5573), 1635-1636.
224. Negrini, S.; Gorgoulis, V. G.; Halazonetis, T. D. Genomic instability--an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 2010, 11 (3), 220-228.
225. Luijsterburg, M. S.; van Attikum, H. Chromatin and the DNA damage response: The cancer connection. Mol. Oncol., 2011, 5(4), 349-367.
226. Varga-Weisz, P. D.; Becker, P. B. Regulation of higher-order chromatin structures by nucleosome-remodelling factors. Curr. Opin. Genet. Dev., 2006, 16 (2), 151-156.
227. Clapier, C. R.; Cairns, B. R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem., 2009, 78 273-304.
228. Saha, A.; Wittmeyer, J.; Cairns, B. R. Chromatin remodelling: the industrial revolution of DNA around histones. Nat. Rev. Mol. Cell Biol., 2006, 7 (6), 437-447.
229. Hargreaves, D. C.; Crabtree, G. R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res., 2011, 21 (3), 396-420.
230. Jackson, S. P.; Bartek, J. The DNA-damage response in human biology and disease. Nature, 2009, 461 (7267), 1071-1078.
231. Garavito, R. M.; Mulichak, A. M. The structure of mammalian cyclooxygenases. Annu. Rev. Biophys. Biomol. Struct., 2003, 32 183-206.
232. Kis, B.; Snipes, J. A.; Isse, T.; Nagy, K.; Busija, D. W. Putative cyclooxygenase-3 expression in rat brain cells. J. Cereb. Blood Flow Metab., 2003, 23 (11), 1287-1292.
233. Chandrasekharan, N. V.; Dai, H.; Roos, K. L.; Evanson, N. K.; Tomsik, J.; Elton, T. S.; Simmons, D. L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U S A, 2002, 99 (21), 13926-13931.
234. Wang, D.; Dubois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 2010, 29 (6), 781-788.
235. Cao, Y.; Prescott, S. M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell Physiol., 2002, 190 (3), 279-286.
236. Mino, T.; Sugiyama, E.; Taki, H.; Kuroda, A.; Yamashita, N.; Maruyama, M.; Kobayashi, M. Interleukin-1alpha and tumor necrosis factor alpha synergistically stimulate prostaglandin E2- dependent production of interleukin-11 in rheumatoid synovial fibroblasts. Arthritis Rheum., 1998, 41 (11), 2004-2013.
237. Sheehan, K. M.; Sheahan, K.; O'Donoghue, D. P.; MacSweeney, F.; Conroy, R. M.; Fitzgerald, D. J.; Murray, F. E. The relationship between cyclooxygenase-2 expression and colorectal cancer. Jama, 1999, 282 (13), 1254-1257.
238. Romagnolo, D. F.; Papoutsis, A. J.; Selmin, O. Nutritional targeting of cyclooxygenase-2 for colon cancer prevention. Inflamm. Allergy Drug Targets, 2010, 9 (3), 181-191.
239. Surh, Y. J.; Kundu, J. K. Signal transduction network leading to COX-2 induction: a road map in search of cancer chemopreventives. Arch. Pharm. Res., 2005, 28 (1), 1-15.
240. Wang, H.; Khor, T. O.; Saw, C. L.; Lin, W.; Wu, T.; Huang, Y.; Kong, A. N. Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal macrophages by polyunsaturated fatty acids docosahexaenoic acid and eicosapentaenoic acid. Mol. Pharm., 2010, 7 (6), 2185-2193.
241. Chun, K. S.; Surh, Y. J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem. Pharmacol., 2004, 68 (6), 1089-1100.
242. Ehrlich, M.; Gama-Sosa, M. A.; Huang, L. H.; Midgett, R. M.; Kuo, K. C.; McCune, R. A.; Gehrke, C. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res., 1982, 10 (8), 2709-2721.
243. Daura-Oller, E.; Cabre, M.; Montero, M. A.; Paternain, J. L.; Romeu, A. Specific gene hypomethylation and cancer: new insights into coding region feature trends. Bioinformation, 2009, 3 (8), 340-343.
244. Chen, J. K.; Taipale, J.; Young, K. E.; Maiti, T.; Beachy, P. A. Small molecule modulation of Smoothened activity. Proc Natl Acad Sci U S A, 2002, 99 (22), 14071-14076.
245. Taipale, J.; Cooper, M. K.; Maiti, T.; Beachy, P. A. Patched acts catalytically to suppress the activity of Smoothened. Nature, 2002, 418 (6900), 892-897.
246. Lee, S. W.; Moskowitz, M. A.; Sims, J. R. Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int. J. Mol. Med., 2007, 19 (3), 445-451.
247. Adolphe, C.; Hetherington, R.; Ellis, T.; Wainwright, B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res., 2006, 66 (4), 2081-2088.
248. Athar, M.; Li, C.; Tang, X.; Chi, S.; Zhang, X.; Kim, A. L.; Tyring, S. K.; Kopelovich, L.; Hebert, J.; Epstein, E. H., Jr.; Bickers, D. R.; Xie, J. Inhibition of smoothened signaling prevents ultraviolet B- induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res., 2004, 64 (20), 7545-7552.
249. Sarkar, F. H.; Li, Y.; Wang, Z.; Kong, D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev., 2010, 29 (3), 383-394.
250. Marini, K. D.; Payne, B. J.; Watkins, D. N.; Martelotto, L. G. Mechanisms of Hedgehog signalling in cancer. Growth Factors, 2011, 29(6), 221-234.
251. Gupta, S.; Takebe, N.; Lorusso, P. Targeting the Hedgehog pathway in cancer. Ther. Adv. Med. Oncol., 2010, 2 (4), 237-250.
252. Nakamura, M.; Kubo, M.; Yanai, K.; Mikami, Y.; Ikebe, M.; Nagai, S.; Yamaguchi, K.; Tanaka, M.; Katano, M. Anti-patched-1 antibodies suppress hedgehog signaling pathway and pancreatic cancer proliferation. Anticancer Res., 2007, 27 (6A), 3743-3747.
253. Hunt, R.; Bragina, O.; Drews, M.; Kasak, L.; Timmusk, S.; Valkna, A.; Kogerman, P.; Jarvekulg, L. Generation and characterization of mouse monoclonal antibody 5E1 against human transcription factor GLI3. Hybridoma (Larchmt), 2007, 26 (4), 231-240.
254. Stecca, B.; Mas, C.; Ruiz i Altaba, A. Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol. Med., 2005, 11 (5), 199-203.
255. Jenuwein, T.; Allis, C. D. Translating the histone code. Science, 2001, 293 (5532), 1074-1080.
256. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F. H. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res., 2010, 27 (6), 1027-1041.
257. Ha, T. Y. MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw., 2011, 11 (3), 135-154.
258. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136 (2), 215-233.
259. Selbach, M.; Schwanhausser, B.; Thierfelder, N.; Fang, Z.; Khanin, R.; Rajewsky, N. Widespread changes in protein synthesis induced by microRNAs. Nature, 2008, 455 (7209), 58-63.
260. Lee, Y.; Kim, M.; Han, J.; Yeom, K. H.; Lee, S.; Baek, S. H.; Kim, V. N. MicroRNA genes are transcribed by RNA polymerase II. Embo. J., 2004, 23 (20), 4051-4060.
261. O'Donnell, K. A.; Wentzel, E. A.; Zeller, K. I.; Dang, C. V.; Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435 (7043), 839-843.
262. O'Connell, R. M.; Rao, D. S.; Chaudhuri, A. A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol., 2010, 10 (2), 111-122.
263. He, L.; Thomson, J. M.; Hemann, M. T.; Hernando-Monge, E.; Mu, D.; Goodson, S.; Powers, S.; Cordon-Cardo, C.; Lowe, S. W.; Hannon, G. J.; Hammond, S. M. A microRNA polycistron as a potential human oncogene. Nature, 2005, 435 (7043), 828-833.
264. Shenouda, S. K.; Alahari, S. K. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev., 2009, 28 (3-4), 369-378.
265. Nelson, D. E.; Ihekwaba, A. E.; Elliott, M.; Johnson, J. R.; Gibney, C. A.; Foreman, B. E.; Nelson, G.; See, V.; Horton, C. A.; Spiller, D. G.; Edwards, S. W.; McDowell, H. P.; Unitt, J. F.; Sullivan, E.; Grimley, R.; Benson, N.; Broomhead, D.; Kell, D. B.; White, M. R. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science, 2004, 306 (5696), 704-708.
266. Escarcega, R. O.; Fuentes-Alexandro, S.; Garcia-Carrasco, M.; Gatica, A.; Zamora, A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol), 2007, 19 (2), 154-161.
267. Moi, P.; Chan, K.; Asunis, I.; Cao, A.; Kan, Y. W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U S A, 1994, 91 (21), 9926-9930.
268. Chan, J. Y.; Cheung, M. C.; Moi, P.; Chan, K.; Kan, Y. W. Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization. Hum. Genet., 1995, 95 (3), 265-269.
269. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J. D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev., 1999, 13 (1), 76-86.
270. Li, W.; Kong, A. N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog., 2009, 48 (2), 91-104.
271. Venugopal, R.; Jaiswal, A. K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element- mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U S A, 1996, 93 (25), 14960-14965.
272. Solis, W. A.; Dalton, T. P.; Dieter, M. Z.; Freshwater, S.; Harrer, J. M.; He, L.; Shertzer, H. G.; Nebert, D. W. Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem. Pharmacol., 2002, 63 (9), 1739-1754.
273. Hayes, J. D.; Chanas, S. A.; Henderson, C. J.; McMahon, M.; Sun, C.; Moffat, G. J.; Wolf, C. R.; Yamamoto, M. The Nrf2 transcription factor contributes both to the basal expression of glutathione S- transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem. Soc. Trans., 2000, 28 (2), 33-41.
274. Yueh, M. F.; Tukey, R. H. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J. Biol. Chem., 2007, 282 (12), 8749-8758.
275. Maher, J. M.; Dieter, M. Z.; Aleksunes, L. M.; Slitt, A. L.; Guo, G.; Tanaka, Y.; Scheffer, G. L.; Chan, J. Y.; Manautou, J. E.; Chen, Y.; Dalton, T. P.; Yamamoto, M.; Klaassen, C. D. Oxidative and electrophilic stress induces multidrug resistance-associated protein transporters via the nuclear factor-E2-related factor-2 transcriptional pathway. Hepatology, 2007, 46 (5), 1597-1610.
276. Nguyen, T.; Nioi, P.; Pickett, C. B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem., 2009, 284 (20), 13291-13295.
277. Keum, Y. S. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann. N Y Acad. Sci., 2012, 1229 184-189.
278. Carpenter, C. L.; Duckworth, B. C.; Auger, K. R.; Cohen, B.; Schaffhausen, B. S.; Cantley, L. C. Purification and characterization of phosphoinositide 3-kinase from rat liver. J. Biol. Chem., 1990, 265 (32), 19704-19711.
279. Kalaany, N. Y.; Sabatini, D. M. Tumours with PI3K activation are resistant to dietary restriction. Nature, 2009, 458 (7239), 725-731.
280. Cheng, K. Y.; Lowe, E. D.; Sinclair, J.; Nigg, E. A.; Johnson, L. N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. Embo. J., 2003, 22 (21), 5757-5768.
281. Soung, N. K.; Park, J. E.; Yu, L. R.; Lee, K. H.; Lee, J. M.; Bang, J. K.; Veenstra, T. D.; Rhee, K.; Lee, K. S. Plk1-dependent and - independent roles of an ODF2 splice variant, hCenexin1, at the centrosome of somatic cells. Dev. Cell, 2009, 16 (4), 539-550.
282. Liu, X.; Erikson, R. L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U S A, 2003, 100 (10), 5789-5794.
283. Medema, R. H.; Lin, C. C.; Yang, J. C. Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC. Clin. Cancer Res., 2011, 17 (20), 6459-6466.
284. Petermann, E.; Keil, C.; Oei, S. L. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol. Life Sci., 2005, 62 (7-8), 731-738.
285. Giansanti, V.; Dona, F.; Tillhon, M.; Scovassi, A. I. PARP inhibitors: new tools to protect from inflammation. Biochem. Pharmacol., 2011, 80 (12), 1869-1877.
286. Beneke, S. Poly(ADP-ribose) polymerase activity in different pathologies--the link to inflammation and infarction. Exp. Gerontol., 2008, 43 (7), 605-614.
287. Huang, D.; Yang, C. Z.; Yao, L.; Wang, Y.; Liao, Y. H.; Huang, K. Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina. Arch. Med. Res., 2008, 39 (8), 775-784.
288. Naura, A. S.; Datta, R.; Hans, C. P.; Zerfaoui, M.; Rezk, B. M.; Errami, Y.; Oumouna, M.; Matrougui, K.; Boulares, A. H. Reciprocal regulation of iNOS and PARP-1 during allergen- induced eosinophilia. Eur. Respir. J., 2009, 33 (2), 252-262.
289. Ornitz, D. M.; Itoh, N. Fibroblast growth factors. Genome Biol., 2001, 2 (3), REVIEWS3005.
290. Khurana, R.; Simons, M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc. Med., 2003, 13 (3), 116-122.
291. Browning, D. D.; Kwon, I. K.; Wang, R. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med. Chem., 2010, 2 (1), 65-80.
292. Klampfer, L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets, 2006, 6 (2), 107-121.
293. Lie, D. C.; Colamarino, S. A.; Song, H. J.; Desire, L.; Mira, H.; Consiglio, A.; Lein, E. S.; Jessberger, S.; Lansford, H.; Dearie, A. R.; Gage, F. H. Wnt signalling regulates adult hippocampal neurogenesis. Nature, 2005, 437 (7063), 1370-1375.
294. Cadigan, K. M.; Nusse, R. Wnt signaling: a common theme in animal development. Genes Dev., 1997, 11 (24), 3286-3305.
295. Weetman, A. P. Cellular immune responses in autoimmune thyroid disease. Clin. Endocrinol. (Oxf), 2004, 61 (4), 405-413.
296. Nelson, W. J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 2004, 303 (5663), 1483-1487.
297. Taketo, M. M. Shutting down Wnt signal-activated cancer. Nat. Genet., 2004, 36 (4), 320-322.
298. MacDonald, B. T.; Tamai, K.; He, X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell, 2009, 17 (1), 9-26.
299. Luu, H. H.; Zhang, R.; Haydon, R. C.; Rayburn, E.; Kang, Q.; Si, W.; Park, J. K.; Wang, H.; Peng, Y.; Jiang, W.; He, T. C. Wnt/beta- catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets, 2004, 4 (8), 653-671.
300. Menendez, J. A.; Vazquez-Martin, A.; Garcia-Villalba, R.; Carrasco-Pancorbo, A.; Oliveras-Ferraros, C.; Fernandez-Gutierrez, A.; Segura-Carretero, A. tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra- Virgin Olive Oil (EVOO). BMC Cancer, 2008, 8 377.
301. Palozza, P.; Colangelo, M.; Simone, R.; Catalano, A.; Boninsegna, A.; Lanza, P.; Monego, G.; Ranelletti, F. O. Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines. Carcinogenesis, 2010, 31 (10), 1813-1821.
302. Tan, A. C.; Konczak, I.; Sze, D. M.; Ramzan, I. Molecular pathways for cancer chemoprevention by dietary phytochemicals. Nutr. Cancer, 2011, 63 (4), 495-505.
303. de Kok, T. M.; van Breda, S. G.; Briede, J. J. Genomics-Based Identification of Molecular Mechanisms behind the Cancer Preventive Action of Phytochemicals: Potential and Challenges. Curr. Pharm. Biotechnol., 2012, 13 (1), 255-264.
304. National Institutes of Health. www.clinicaltrials.gov Accessed on Feb. 25, 2012.
305. Kwon, K. H.; Barve, A.; Yu, S.; Huang, M. T.; Kong, A. N. Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin., 2007, 28 (9), 1409-1421.
306. Klein, R. D. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat. Res., 2005, 576 (1-2), 111-119.
307. Wu, T. Y.; Saw, C. L.; Khor, T. O.; Pung, D.; Boyanapalli, S. S.; Kong, A. N. In vivo pharmacodynamics of indole-3-carbinol in the inhibition of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: Involvement of Nrf2 and cell cycle/apoptosis signaling pathways. Mol. Carcinog., 2011, 51(10), 761-770.
308. Khor, T. O.; Huang, Y.; Wu, T. Y.; Shu, L.; Lee, J.; Kong, A. N. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol., 2011, 82 (9), 1073-1078.
309. Barve, A.; Khor, T. O.; Reuhl, K.; Reddy, B.; Newmark, H.; Kong, A. N. Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr. Cancer, 2010, 62 (6), 789-794.
310. Khor, T. O.; Yu, S.; Barve, A.; Hao, X.; Hong, J. L.; Lin, W.; Foster, B.; Huang, M. T.; Newmark, H. L.; Kong, A. N. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 2009, 69 (17), 7096-7102.
311. Barve, A.; Khor, T. O.; Nair, S.; Reuhl, K.; Suh, N.; Reddy, B.; Newmark, H.; Kong, A. N. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int. J. Cancer, 2009, 124 (7), 1693-1699.
312. Saw, C. L.; Huang, M. T.; Liu, Y.; Khor, T. O.; Conney, A. H.; Kong, A. N. Impact of Nrf2 on UVB-induced skin inflammation/ photoprotection and photoprotective effect of sulforaphane. Mol. Carcinog., 2011, 50 (6), 479-486.
313. Kasinski, A. L.; Du, Y.; Thomas, S. L.; Zhao, J.; Sun, S. Y.; Khuri, F. R.; Wang, C. Y.; Shoji, M.; Sun, A.; Snyder, J. P.; Liotta, D.; Fu, H. Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol. Pharmacol., 2008, 74 (3), 654-661.
314. Eisenstein, S. A.; Clapper, J. R.; Holmes, P. V.; Piomelli, D.; Hohmann, A. G. A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharmacol. Res., 2011, 61 (5), 419-429.
315. Cohen, R.; Schwartz, B.; Peri, I.; Shimoni, E. Improving bioavailability and stability of genistein by complexation with high-amylose corn starch. J. Agric. Food Chem., 2011, 59 (14), 7932-7938.
316. Clas, S. D. The importance of characterizing the crystal form of the drug substance during drug development. Curr. Opin. Drug Discov. Devel., 2003, 6 (4), 550-560.
317. Soh, J. L. P.; Heng, P. W. S., In Vitro Dissolution of Pharmaceutical Solids. In Oral Bioavailability - Basic Principles, Advanced Concepts, and Applications, Hu, M.; Li, X. L., Eds.; Wiley & Sons: Hoboken, 2011; pp 39-49.
318. Bailey, D. G.; Dresser, G. K. Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs, 2004, 4 (5), 281-297.
319. Leclercq, I.; Desager, J. P.; Horsmans, Y. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin. Pharmacol. Ther., 1998, 64 (2), 144-149.
320. Tompkins, L. M.; Wang, H., Liver Drug Metabolism. In Oral Bioavailability - Basic Principles, Advanced Concepts, and Applications, Hu, M.; Li, X., Eds.; John Wiley & Sons: Hoboken, 2011; pp 127-144.
321. Lambert, J. D.; Sang, S.; Yang, C. S. Possible controversy over dietary polyphenols: benefits vs risks. Chem. Res. Toxicol., 2007, 20 (4), 583-585.
322. Galati, G.; Lin, A.; Sultan, A. M.; O'Brien, P. J. Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med., 2006, 40 (4), 570-580.
323. Isbrucker, R. A.; Edwards, J. A.; Wolz, E.; Davidovich, A.; Bausch, J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem. Toxicol., 2006, 44 (5), 636-650.
324. Collins, N.; Tighe, A. P.; Brunton, S. A.; Kris-Etherton, P. M. Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J. Am. Coll. Nutr., 2008, 27 (6), 659-666.